Lumen Freedom Announces the Supply of Their First Wireless Electric Vehicle Charging (WEVC) System, for McLaren’s Ultimate Series Hyper-GT, the Speedtail
25.8.2020 08:00:00 EEST | Business Wire | Press release
Lumen Freedom, a world leading manufacturer of Wireless Electric Vehicle Charging (WEVC) systems, today announce the supply of their first Wireless Electric Vehicle Charging system, to McLaren Automotive for the Speedtail Hyper-GT, as featured by the McLaren Tech Club.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200824005651/en/
McLaren Automotive Limited
WEVC will soon become the charging mode of choice with many vehicle manufacturers planning implementation of this new technology on future models.
WEVC provides hands free, efficient, clean and unobtrusive charging with performance levels equal to or greater than that of cable systems.
From static to Dynamic non-stop highway charging, the development and adoption of WEVC makes EV driving even more appealing and eliminates visual urban pollution. WEVC is also an enabler for the future development and uptake of autonomous driving.
Lumen Freedom operates from an advanced, secure, technical centre based in Melbourne Australia.
PROUDLY MADE IN AUSTRALIA
To learn more about Lumen Freedom, visit http://www.lumenfreedom.com/
To learn more about McLaren, visit http://www.mclaren.com/
About the Lumen Group
The Lumen Group is a leading integrator of automotive systems. Lumen offers a full-service supply capability from design, through to manufacturing on a global basis. With over 30 years of experience in the automotive industry, Lumen is known for being highly efficient and flexible in meeting customer’s needs.
Lumen Freedom, a member of the Lumen group of companies, is dedicated to the design, manufacture and integration of Wireless Electric Vehicle Charging (WEVC) systems. Lumen Freedom holds a license from WiTricity for the development and commercialization of WEVC.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200824005651/en/
Contact information
Rod Wilson, Lumen Freedom
rod@lumenfreedom.com.au
+61 499 055 200
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives European Union Approval for Restylane ® Shaype™: the First-and-Only Bone-Mimicking Hyaluronic Acid Injectable for Facial Shaping11.8.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD) today announced that Restylane Shaype has been approved in the EU under the Medical Device Regulation for temporary augmentation of the chin region. Engineered for deep injection to build and shape on bone, Restylane Shaype delivers a unique bone-mimicking effect, enabling immediate, natural-looking structural enhancement in the lower face without surgery.1-3 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260810880899/en/ The lower face plays a pivotal role in overall facial balance, influencing proportions and profile.2 This region is an increasing area of concern for patients, with around one in four people expressing concerns related to lower face sagging and chin shape.5 When asked about their facial priorities, a third of people pointed out issues with their chin shape – a key contributor to facial definition and structural harmony.5 Genetic factors and age-related changes can lead to reduced chin d
Stonebranch is Again Named a Leader in the 2026 Gartner ® Magic Quadrant ™ for Service Orchestration and Automation Platforms (SOAPs)10.8.2026 18:00:00 EEST | Press release
Stonebranch, a leading provider of service orchestration and automation solutions, today announced that it has once again been positioned by Gartner as a Leader in the Magic Quadrant for Service Orchestration and Automation Platforms (SOAPs) for its offering, Universal Automation Center™ (UAC).1 “We’re pleased to be recognized as a Leader for the third year in a row,” said Giuseppe Damiani, CEO at Stonebranch. “To us, this recognition reflects our advancements in helping enterprises orchestrate increasingly complex IT operations with confidence. As organizations modernize their automation strategies and adopt AI, UAC provides the centralized orchestration control plane required to unify traditional automation with AI models and agentic systems. With built-in capabilities like Robi AI, UAC’s agentic copilot, we’re making it easier than ever for teams to build, manage, and optimize automation at enterprise scale.” Stonebranch UAC helps organizations unify, manage, and scale automation ac
Frontgrade Expands Huntsville Presence with Advanced R&D Center Supporting Next-Generation Space and Defense Missions10.8.2026 17:09:00 EEST | Press release
Frontgrade Technologies ("Frontgrade"), a leading provider of mission-critical electronics and integrated technologies, today announced the opening of its eighth U.S. location in Huntsville, Alabama. Located in Cummings Research Park, the new Advanced Research & Development Center will accelerate the development of next-generation mission processing technologies supporting critical space, defense, intelligence, and national security missions. The Huntsville center expands Frontgrade's engineering capabilities while placing research teams closer to customers, government organizations, industry partners, and leading academic institutions. By working within one of the nation's premier aerospace and defense ecosystems, Frontgrade will accelerate technology development, strengthen customer collaboration, and help deliver mission-ready capabilities faster. “Bringing Frontgrade’s capabilities to Huntsville is a meaningful milestone for me, both personally and professionally. For decades, this
Brightfin Appoints Preeti Shukla as Chief Product and AI Officer10.8.2026 16:00:00 EEST | Press release
Brightfin, the only IT Financial Management (ITFM) and Technology Expense Management solution built natively on ServiceNow, today announced the appointment of Preeti Shukla as Chief Product and AI Officer (CPAIO). In this newly created role, Shukla will lead product strategy and artificial intelligence across the Brightfin platform, advancing the company's mission to make every technology decision grounded in financial truth, operational clarity, and intelligent automation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260810283143/en/ Preeti Shukla, CPAIO of Brightfin Shukla brings two decades of experience building and scaling customer-facing, enterprise-grade B2B SaaS, fintech, and marketplace products across Fortune 100 companies and high-growth startups, including leadership roles at Workday and Oracle. A recognized authority on applied AI, she is a Gartner-recognized thought leader and author on AI SaaS and product en
BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration10.8.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, and Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced a multi-part collaboration including: a clinical collaboration to evaluate drug combinations incorporating select clinical-stage oncology assets from BeOne with any of Revolution Medicines’ four clinical RAS(ON) inhibitors, and a separate regional rights agreement granting BeOne exclusive development and commercialization rights to these Revolution Medicines assets in select Asian markets. Clinical collaboration will explore potential targeted combination approaches for patients with RAS-addicted cancers Potential drug combinations for development as part of the clinical collaboration will include certain BeOne assets and Revolution Medicines’ four clinical RAS(ON) inhibitors: daraxonrasib, a RAS(ON) multi-selective inhibitor; zo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom